NCT05014698Terminated

IDEntification of New Predisposition Genes in Differentiated THYroid Cancer

Source: ClinicalTrials.gov · Last updated 28 Jan 2026

Reason given: end-of-study visit not completed within the protocol timeframe

Brief summary (registry, in English)

The purpose of this research is to find new predisposition genes for differentiated thyroid cancer (DTC).

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Subjects with another syndromic predisposition to thyroid cancer (Cowden, Werner, PAF)

Subject refusing to participate
Subjects with a causal mutation identified in the predisposition genes: BAP1 and DICER 1
Subjects under guardianship, curatorship or safeguard of justice or not socially insured

Probant subjects
Minor or adult subject
Adult subject or legal guardian for minor subjects agreeing to sign the study consent and biospecimen consent
Subject with differentiated thyroid cancer without an identified causative mutation in the BAP1 and DICER 1 predisposition genes
Patient affiliated to a valid social security plan
- Relative subjects
Adult subjects
Subject agreeing to sign the study consent and the biocollection consent
Subject with differentiated thyroid cancer or from a family with several cases of differentiated thyroid cancer without a causal mutation identified in the BAP1 and DICER 1 predisposition genes
Patient affiliated to a social security plan

Age in the registry: 8 years to - · Sex: All · Accepts healthy volunteers

Sites in registry order. Save your city in your profile to sort them by distance.

Site	City	Country	Site status
Vendée Hospital	La Roche-sur-Yon	France	Unknown status
Nantes University Hospital	Nantes	France	Unknown status

This page is information, not medical advice. Discuss any trial with your doctor.